Purchase Order HHSN272201501309P

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on September 3, 2022, for gene synthesis plasmid preparation services, with a firm fixed price ceiling of $48,665.65. Place of performance is Piscataway, New Jersey. The work supports the FY26 UDO Initiative and was sourced through a pre-solicitation opportunity posted August 24, 2022, with a September 2 deadline. Ultimate completion is scheduled for September 29, 2022.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for sequencing and gene synthesis services for 100 samples on March 17, 2022, with a ceiling value of $15,389.60. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside designation and an ultimate completion date of March 16, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $17,209.00 on September 18, 2023, for custom gene synthesis and expression services. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The ultimate completion date is December 31, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $14,756.36 on September 13, 2021, for sequencing services under the FY26 UDO Initiative. Performance is at Genscript's facility in Piscataway, New Jersey. The order carries a firm fixed price and was completed by December 31, 2021.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $1,147,346.00 on September 26, 2019, for customized biologicals under firm fixed pricing. Performance is located in Piscataway, New Jersey. The order has no small business set-aside and carried an ultimate completion date of September 25, 2020. The originating pre-solicitation was posted September 3, 2019, with a due date of September 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $14,979.75 on August 29, 2024, for monoclonal antibodies and plasmids services. The order is firm fixed price with no small business set-aside. Performance occurs in Piscataway, New Jersey. The modification de-obligates excess funds, with ultimate completion scheduled for May 18, 2026.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $70,622.20 on August 5, 2020, for customized RAB expression synthesis under the FY26 UDO Initiative. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no small business set-aside. The ultimate completion date is September 28, 2020. The requirement originated from a pre-solicitation opportunity posted July 24, 2020, with an August 3, 2020 deadline.</p>

The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on August 23, 2023, for DNA services valued at $34,502.16. The order covers gene synthesis, VectorArk cloning, and express plasmid preparation. Performance occurs in Piscataway, New Jersey. The services support development of peptide and protein immunogens and DNA constructs for MPER-scaffolded proteins used in vaccine research against HIV, influenza, Ebola, Marburg, and other infectious...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $13,459 purchase order to Genscript USA Inc. to provide custom subcloning and antibody sequencing services in support of the agency's biomedical research efforts. Work will be performed by Genscript in Piscataway, New Jersey over a three-month period concluding in early October 2023. The firm fixed price contract was awarded under an unidentified agency-wide...